SUVOREXANT - AN OVERVIEW

Avoid concomitant usage of tucatinib with CYP3A substrates, where minimum concentration adjustments may possibly bring on major or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose Based on product or service labeling.Stiripentol can be a CYP3A4 inhibitor and inducer. Keep an eye on CYP3A4 substrates coadministered with stiri